Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Speaking up for our patients, and ourselves.
Zimmerman T. Zimmerman T. J Healthc Risk Manag. 2011;30(4):1-2. doi: 10.1002/jhrm.20062. J Healthc Risk Manag. 2011. PMID: 21506196 No abstract available.
The importance of reaching out.
Zimmerman T. Zimmerman T. J Healthc Risk Manag. 2010;30(2):1-2. doi: 10.1002/jhrm.20046. J Healthc Risk Manag. 2010. PMID: 20979158 No abstract available.
A problem with a unique profile in healthcare.
Zimmerman T. Zimmerman T. J Healthc Risk Manag. 2011;30(3):1-2. doi: 10.1002/jhrm.20054. J Healthc Risk Manag. 2011. PMID: 21351190 No abstract available.
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR, Ailawadhi S, Siegel DS, Heffner LT, Somlo G, Jagannath S, Zimmerman TM, Munshi NC, Madan S, Chanan-Khan A, Lonial S, Chandwani S, Minasyan A, Ruehle M, Barmaki-Rad F, Abdolzade-Bavil A, Rharbaoui F, Herrmann-Keiner E, Haeder T, Wartenberg-Demand A, Anderson KC. Kelly KR, et al. Among authors: zimmerman tm. Lancet Haematol. 2021 Sep 13:S2352-3026(21)00208-8. doi: 10.1016/S2352-3026(21)00208-8. Online ahead of print. Lancet Haematol. 2021. PMID: 34529955
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Jasielec JK, et al. Among authors: zimmerman tm. Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522. Blood. 2020. PMID: 32735641 Free PMC article. Clinical Trial.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Jakubowiak AJ, et al. Among authors: zimmerman tm. Br J Haematol. 2019 Aug;186(4):549-560. doi: 10.1111/bjh.15969. Epub 2019 May 24. Br J Haematol. 2019. PMID: 31124580 Free PMC article. Clinical Trial.
38 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page